Ovid Therapeutics
$1.51
99
-$0.05-3.21% Monday 21:00
Statistics
Day High
1.6
Day Low
1.47
52W High
2.01
52W Low
0.24
Volume
1,769,485
Avg. Volume
1,623,854
Mkt Cap
107.53M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
16MarExpected
Expected EPS
-0.11708
Actual EPS
N/A
Financials
-4,670.14%Profit Margin
Unprofitable1.13MRevenue
-52.87MNet Income
Analyst Ratings
$3.50Average Price Target
The highest estimate is 5.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow OVID. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
PTC Therapeutics
PTCT
Mkt Cap5.4B
Biogen
BIIB
Mkt Cap22.63B
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Acadia Pharmaceuticals
ACAD
Mkt Cap3.83B
Anavex Life Sciences
AVXL
Mkt Cap684.57M
Neurocrine Biosciences
NBIX
Mkt Cap14.28B
About
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Show more...
CEO
Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.
Employees
23
Country
US
ISIN
US6904691010
Listings
0 Comments
Share your thoughts
FAQ
What is Ovid Therapeutics stock price today?▼
The current price of OVID is $1.51 USD — it has decreased by -3.21% in the past 24 hours. Watch Ovid Therapeutics stock price performance more closely on the chart.
What is Ovid Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Ovid Therapeutics stocks are traded under the ticker OVID.
Is Ovid Therapeutics stock price growing?▼
OVID stock has fallen by -16.57% compared to the previous week, the month change is a -14.2% fall, over the last year Ovid Therapeutics has showed a +128.48% increase.
What is Ovid Therapeutics market cap?▼
Today Ovid Therapeutics has the market capitalization of 107.53M
When is the next Ovid Therapeutics earnings date?▼
Ovid Therapeutics is going to release the next earnings report on March 16, 2026.
What were Ovid Therapeutics earnings last quarter?▼
OVID earnings for the last quarter are -0.17 USD per share, whereas the estimation was -0.15 USD resulting in a -13.41% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Ovid Therapeutics revenue for the last year?▼
Ovid Therapeutics revenue for the last year amounts to 1.13M USD.
What is Ovid Therapeutics net income for the last year?▼
OVID net income for the last year is -52.87M USD.
How many employees does Ovid Therapeutics have?▼
As of February 03, 2026, the company has 23 employees.
In which sector is Ovid Therapeutics located?▼
Ovid Therapeutics operates in the Health Care sector.
When did Ovid Therapeutics complete a stock split?▼
Ovid Therapeutics has not had any recent stock splits.
Where is Ovid Therapeutics headquartered?▼
Ovid Therapeutics is headquartered in New York, US.